+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cancer / Tumor Profiling - Global Strategic Business Report

  • PDF Icon

    Report

  • 376 Pages
  • September 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 4804691
The global market for Cancer / Tumor Profiling is estimated at US$10.3 Billion in 2023 and is projected to reach US$19.8 Billion by 2030, growing at a CAGR of 9.8% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

The growth in the cancer/tumor profiling market is driven by several factors, including advancements in molecular profiling technologies, increased adoption of liquid biopsies, and the integration of AI and machine learning. The development of single-cell sequencing technologies offers granular insights into tumor heterogeneity, identifying subpopulations driving disease progression and therapy resistance. This level of detail supports the creation of more effective treatment strategies. Moreover, AI and ML enhance the analysis of complex molecular data, improving the accuracy of profiling and enabling the prediction of patient outcomes. The expanding capabilities of these technologies, combined with their integration into clinical practice, promise more personalized and responsive cancer treatments, ultimately leading to better patient outcomes and continuous innovation in oncology.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Immunoassays Technology segment, which is expected to reach US$6.2 Billion by 2030 with a CAGR of a 9.3%. The Next Generation Sequencing Technology segment is also set to grow at 10.8% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $3.7 Billion in 2023, and China, forecasted to grow at an impressive 10.6% CAGR to reach $1.6 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Cancer / Tumor Profiling Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Cancer / Tumor Profiling Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Cancer / Tumor Profiling Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as Caris Life Sciences, Genomic Health, Inc., Helomics Corporation, and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 55 Featured):

  • Caris Life Sciences
  • Genomic Health, Inc.
  • Helomics Corporation
  • HTG Molecular Diagnostics, Inc.
  • Illumina, Inc.
  • Nanostring Technologies, Inc.
  • NeoGenomics Laboratories, Inc.
  • Oxford Gene Technology
  • Qiagen NV
  • Ribomed Biotechnologies, Inc.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Rise in Cancer Incidence Fosters Growth in Cancer / Tumor Profiling Market
  • Select Cancer Statistics
  • Total Number of New Cancer Cases by Type: 2022
  • Total Number of Cancer Deaths by Type: 2022
  • Cancer Incidence by Region: 2022
  • Cancer Mortality by Region: 2022
  • Tumor Profiling: At Zenith of Efforts to Expedite Transition from Histologic to Precision Cancer Treatment
  • Economic Frontiers: Trends, Trials & Transformations
  • In a World Torn by Geopolitical Instability & War, Steadfastness of Global GDP Becomes Increasingly Unpredictable Given the Many Direct and Indirect Economic Repercussions: World Economic Growth Projections (Real Gross Domestic Product (GDP), Annual % Change) for the Years 2022 Through 2025
  • All Eyes on Global Inflation, the Main Risk Factor in Global Markets: Global Headline Inflation Rates (In %) for the Years 2019 through 2025
  • With Oil Prices Influencing the Rate of inflation, it Remains the Most Watched Commodity in Global Markets: Global Average Annual Brent Crude Oil Price (In US$ Per Barrel) for Years 2019 through 2025
  • Global Market Analysis and Prospects
  • Global Cancer/Tumor Profiling Market Looks Forward to Prolific Growth
  • Genomic Profiling, NGS, Breast Cancer & Research: Thriving Segments of Cancer/Tumor Profiling Market
  • NGS as Primary Technology Segment
  • Breast Cancer & Pharmaceutical Segments to Exhibit Solid Gains
  • Research Rules while Treatment Selection Posts Fastest Growth
  • North America Clinches Commanding Stake on Global Cancer/Tumor Profiling Market
  • Asia-Pacific Emerges as Lucrative Market
  • Pulsating Trends Favoring Expansion of Cancer/Tumor Profiling Market
  • Select Market Drivers
  • Market Opportunities
  • Competitive Landscape: Innovation and R&D Focus amid Fierce Competition
  • Cancer / Tumor Profiling - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • Recent Market Activity
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Molecular Profiling Paves the Way for Personalized Cancer Treatment
  • Introduction of Tumour Profiling Techniques Ensures Timely Treatment for Cancer Patients
  • Application of Cancer/Tumor Profiling in Cancer Research Sees Significant Growth
  • Transformative Advances in Tumor Profiling Technologies Revolutionize Cancer Treatment
  • Liquid Biopsy: A Transformative Tool in Cancer Profiling, Diagnostics, and Monitoring
  • Precision Oncology Holds Upside Potential with Advancements in Multi-Omics Tumor Profiling
  • Leveraging AI and Machine Learning in Tumor Profiling Facilitates Cancer Care
  • Precision Oncology Holds Upside Potential with Advancements in Multi-Omics Tumor Profiling
  • Single-Cell Sequencing: Revolutionizing Cancer Research
  • Tumor Profiling: A Catalyst for Precision Companion Diagnostics
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Cancer / Tumor Profiling Market Analysis of Annual Sales in US$ Million for Years 2017 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 3: World Historic Review for Cancer / Tumor Profiling by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • Table 4: World 13-Year Perspective for Cancer / Tumor Profiling by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2017, 2024 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Immunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 6: World Historic Review for Immunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • Table 7: World 13-Year Perspective for Immunoassays by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2024 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for Next Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 9: World Historic Review for Next Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • Table 10: World 13-Year Perspective for Next Generation Sequencing by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2024 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for In-Situ Hybridization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 12: World Historic Review for In-Situ Hybridization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • Table 13: World 13-Year Perspective for In-Situ Hybridization by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2024 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for Polymerase Chain Reaction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 15: World Historic Review for Polymerase Chain Reaction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • Table 16: World 13-Year Perspective for Polymerase Chain Reaction by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2024 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 18: World Historic Review for Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • Table 19: World 13-Year Perspective for Mass Spectrometry by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2024 & 2030
  • Table 20: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 21: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • Table 22: World 13-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2024 & 2030
  • Table 23: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 24: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • Table 25: World 13-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2024 & 2030
  • Table 26: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 27: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • Table 28: World 13-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2024 & 2030
  • Table 29: World Recent Past, Current & Future Analysis for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 30: World Historic Review for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • Table 31: World 13-Year Perspective for Colorectal Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2024 & 2030
  • Table 32: World Recent Past, Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 33: World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • Table 34: World 13-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2024 & 2030
  • Table 35: World Recent Past, Current & Future Analysis for Melanoma Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 36: World Historic Review for Melanoma Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • Table 37: World 13-Year Perspective for Melanoma Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2024 & 2030
  • Table 38: World Recent Past, Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 39: World Historic Review for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • Table 40: World 13-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2024 & 2030
  • Table 41: World Recent Past, Current & Future Analysis for Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 42: World Historic Review for Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • Table 43: World 13-Year Perspective for Research Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2024 & 2030
  • Table 44: World Recent Past, Current & Future Analysis for Clinical Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 45: World Historic Review for Clinical Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • Table 46: World 13-Year Perspective for Clinical Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Cancer / Tumor Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
CANADA
JAPAN
  • Cancer / Tumor Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
CHINA
  • Cancer / Tumor Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
EUROPE
  • Cancer / Tumor Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
FRANCE
  • Cancer / Tumor Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
GERMANY
  • Cancer / Tumor Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
ITALY
UNITED KINGDOM
  • Cancer / Tumor Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
REST OF EUROPE
ASIA-PACIFIC
  • Cancer / Tumor Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
REST OF WORLDIV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Caris Life Sciences
  • Genomic Health, Inc.
  • Helomics Corporation
  • HTG Molecular Diagnostics, Inc.
  • Illumina, Inc.
  • Nanostring Technologies, Inc.
  • NeoGenomics Laboratories, Inc.
  • Oxford Gene Technology
  • Qiagen NV
  • Ribomed Biotechnologies, Inc.

Table Information